Oasmia
  1. Home
  2. About Oasmia
  3. Human Health
  4. Animal Health
  5. Investor Relations
  6. Press releases
  7. Current reports
  8. Share
  9. Calendar
  10. Media Contact
  11. Work at Oasmia
 Home · Contact · Dictionary · Sitemap

New license agreement with Orion Corporation

2008-03-26

Interim report May 2007 - Jan 2008

2008-03-14

Phase III results presented in Copenhagen

2008-03-03

Oasmia presents Phase III-results in Denmark

2008-01-31

Final advice for Paclical Phase III program

2008-01-29

Oasmia announces licensing agreement

2007-11-27

Oasmia presented in Florida

2007-11-05

Oasmia presents in USA

2007-10-09

Oasmia in Barcelona

2007-09-27

Great interest for Oasmia in Budapest

2007-09-20

Oasmia to NGM Equity

2007-09-17

Oasmia publishes Listing Prospectus

2007-09-17

Oasmia presents in Budapest

2007-06-19

“Jackpot in sight for Oasmia”

2007-06-07

Status – listing of Oasmia

2007-05-29

Very good clinical results for Paclical®

2007-04-16

Unique results for cancer drug

2007-03-27

New drug for treatment of cancer in dog

2007-03-13

OASMIA confirms Orphan Drug Designation

2006-11-30

Oasmia obtains Orphan Drug designation

2006-11-15

Interim report 2006-10-31

2006-10-31

Oasmia Pharmaceutical AB, Vallongatan 1, SE-752 28 Uppsala, Sweden
Telephone +46 18 50 54 40 Fax +46 18 51 08 73 E-mail info@oasmia.com